jakafi miss ep beat driven one-tim revenu
jakafi revenu slightli consensu jakavi royalti
ex-u sale also miss consensu jakafi sale grew y-o-i
driven increas volum higher net price despit impact higher
gross-to-net adjust total revenu benefit one-tim up-front
payment innov partnership china expens
also lower due decreas up-front consider mileston expens paid
decis longer co-fund develop olumi baricitinib
one-tim innov payment lower expens drove ep beat
versu consensu dilut basi guidanc
unchang except decreas non- expens rang
respect updat estim reiter
buy rate po
announc phase studi topic jakafi ruxolitinib cream vitiligo
met primari endpoint improv facial assess vitiligo area
sever index score view larg patient popul clear
unmet need promis applic ruxolitinib cream outsid atop dermat
ad current undergo phase studi pivot phase vitiligo plan
begin end expect safeti packag studi ad
leverag vitiligo although note efficaci read-through
studi difficult given patient differ
multipl regulatori data catalyst expect
may pdufa date jakafi steroid-refractori acut gvhd next
major catalyst data versu best avail therapi expect
end data capmatinib non-smal cell lung cancer nsclc
present novarti american societi clinic oncolog meet
nda expect nda submiss pemigatinib cholangiocarcinoma
complet enrol bladder cancer studi expect
net dbt
regulatori data catalyst
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani focus drug
develop hematology/oncolog
inflamm multipl market product
includ inhibitor jakafi approv
myelofibrosi polycythemia vera olumi
baricitinib approv ra eu us
iclusig cml emerg rich clinic
rate share buy see signific
valu market product jakafi ruxolitinib
mf pv see signific potenti
compani robust pipelin olumi
approv eu us ruxolitinib gvhd ad
fgfr inhibitor liquid solid
po deriv probability-adjust npv analysi includ
jakafi call jakavi ex-u mf pv jakafi/itacitinib gvhd
baricitinib iclusig pemigatinib
ruxolitinib cream earli pipelin asset also includ approx
net cash use wacc termin valu
downsid risk price object weaker-than-expect sale jakafi mf
pv unfavor efficaci and/or safeti data pipelin asset clinic trial
earlier-than-expect more-than-expect competit jakafi approv
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
